Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epidermolysis Bullosa | 9 | 2024 | 10 | 2.390 |
Why?
|
| Epidermolysis Bullosa Dystrophica | 5 | 2022 | 13 | 2.210 |
Why?
|
| Skin Neoplasms | 8 | 2024 | 404 | 1.450 |
Why?
|
| Timolol | 2 | 2018 | 3 | 1.230 |
Why?
|
| Lasers, Dye | 2 | 2022 | 6 | 1.210 |
Why?
|
| Epidermolysis Bullosa, Junctional | 2 | 2023 | 2 | 1.090 |
Why?
|
| Facial Dermatoses | 2 | 2017 | 10 | 1.000 |
Why?
|
| Epidermolysis Bullosa Simplex | 3 | 2021 | 3 | 1.000 |
Why?
|
| Infant | 16 | 2024 | 1527 | 0.940 |
Why?
|
| Skin | 5 | 2022 | 351 | 0.910 |
Why?
|
| Ultraviolet Therapy | 1 | 2023 | 13 | 0.840 |
Why?
|
| Folliculitis | 2 | 2017 | 6 | 0.840 |
Why?
|
| Malassezia | 2 | 2017 | 6 | 0.840 |
Why?
|
| Hypopigmentation | 1 | 2023 | 17 | 0.820 |
Why?
|
| Soft Tissue Injuries | 1 | 2022 | 17 | 0.810 |
Why?
|
| Hemangioma | 2 | 2018 | 27 | 0.740 |
Why?
|
| Tongue Diseases | 1 | 2020 | 4 | 0.730 |
Why?
|
| Conjunctivitis | 1 | 2020 | 5 | 0.730 |
Why?
|
| Skin Abnormalities | 1 | 2020 | 8 | 0.730 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 2021 | 33 | 0.730 |
Why?
|
| Pilomatrixoma | 1 | 2020 | 3 | 0.730 |
Why?
|
| Hair Diseases | 1 | 2020 | 6 | 0.720 |
Why?
|
| Acne Vulgaris | 3 | 2017 | 24 | 0.720 |
Why?
|
| Diaper Rash | 2 | 2014 | 4 | 0.720 |
Why?
|
| Petrolatum | 1 | 2020 | 1 | 0.710 |
Why?
|
| Exanthema | 1 | 2020 | 27 | 0.710 |
Why?
|
| Humans | 49 | 2024 | 59328 | 0.710 |
Why?
|
| Vitiligo | 1 | 2023 | 120 | 0.700 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2018 | 149 | 0.700 |
Why?
|
| Nail Diseases | 1 | 2021 | 49 | 0.700 |
Why?
|
| Xanthomatosis | 1 | 2019 | 8 | 0.680 |
Why?
|
| Child | 17 | 2023 | 4300 | 0.660 |
Why?
|
| Nevus, Pigmented | 3 | 2024 | 20 | 0.640 |
Why?
|
| Hemangioma, Capillary | 1 | 2018 | 1 | 0.630 |
Why?
|
| Drug Dosage Calculations | 1 | 2018 | 6 | 0.600 |
Why?
|
| Pigmentation Disorders | 2 | 2023 | 8 | 0.590 |
Why?
|
| Fractures, Multiple | 1 | 2017 | 2 | 0.570 |
Why?
|
| Menkes Kinky Hair Syndrome | 1 | 2017 | 3 | 0.570 |
Why?
|
| Administration, Topical | 5 | 2020 | 52 | 0.560 |
Why?
|
| Patient Care | 1 | 2017 | 78 | 0.550 |
Why?
|
| Dermatomycoses | 2 | 2008 | 13 | 0.540 |
Why?
|
| Pregnancy Complications | 1 | 2021 | 391 | 0.530 |
Why?
|
| Infant, Newborn | 8 | 2024 | 1311 | 0.520 |
Why?
|
| Child Abuse | 1 | 2017 | 87 | 0.520 |
Why?
|
| Male | 26 | 2024 | 27509 | 0.510 |
Why?
|
| Infant, Premature | 1 | 2017 | 174 | 0.500 |
Why?
|
| Keratin-14 | 2 | 2012 | 2 | 0.490 |
Why?
|
| Diapers, Infant | 1 | 2014 | 2 | 0.460 |
Why?
|
| Sinus Pericranii | 1 | 2014 | 4 | 0.460 |
Why?
|
| Amniotic Band Syndrome | 1 | 2014 | 4 | 0.460 |
Why?
|
| Dermatologic Agents | 1 | 2014 | 21 | 0.450 |
Why?
|
| Scalp | 1 | 2014 | 29 | 0.450 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 465 | 0.450 |
Why?
|
| Veins | 1 | 2014 | 61 | 0.450 |
Why?
|
| Hair | 1 | 2014 | 78 | 0.430 |
Why?
|
| Melanosis | 2 | 2023 | 9 | 0.420 |
Why?
|
| Loose Anagen Hair Syndrome | 1 | 2012 | 1 | 0.420 |
Why?
|
| Retrospective Studies | 12 | 2023 | 5975 | 0.420 |
Why?
|
| Lichen Nitidus | 1 | 2012 | 2 | 0.410 |
Why?
|
| Adolescent | 12 | 2022 | 5917 | 0.410 |
Why?
|
| Diagnosis, Differential | 6 | 2019 | 895 | 0.410 |
Why?
|
| Aminoquinolines | 1 | 2012 | 15 | 0.410 |
Why?
|
| Lichen Planus | 1 | 2012 | 9 | 0.410 |
Why?
|
| Granuloma | 1 | 2012 | 38 | 0.400 |
Why?
|
| Port-Wine Stain | 1 | 2011 | 10 | 0.390 |
Why?
|
| Dermatitis, Allergic Contact | 2 | 2015 | 10 | 0.380 |
Why?
|
| Laser Therapy | 1 | 2011 | 36 | 0.380 |
Why?
|
| Allergens | 2 | 2015 | 43 | 0.380 |
Why?
|
| Consensus | 2 | 2024 | 194 | 0.370 |
Why?
|
| Adjuvants, Immunologic | 1 | 2012 | 228 | 0.360 |
Why?
|
| Female | 22 | 2024 | 30827 | 0.350 |
Why?
|
| Dacryocystitis | 1 | 2009 | 3 | 0.340 |
Why?
|
| Neurofibromatosis 1 | 2 | 2023 | 28 | 0.340 |
Why?
|
| Child, Preschool | 8 | 2020 | 1838 | 0.320 |
Why?
|
| Skin Diseases | 2 | 2020 | 74 | 0.320 |
Why?
|
| Fusarium | 1 | 2008 | 5 | 0.300 |
Why?
|
| Opportunistic Infections | 1 | 2008 | 27 | 0.300 |
Why?
|
| Dermatology | 3 | 2024 | 69 | 0.280 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2024 | 2034 | 0.260 |
Why?
|
| Branchioma | 1 | 2005 | 2 | 0.250 |
Why?
|
| Thyroglossal Cyst | 1 | 2005 | 3 | 0.250 |
Why?
|
| Coloring Agents | 1 | 2005 | 54 | 0.250 |
Why?
|
| Nose Diseases | 1 | 2005 | 9 | 0.250 |
Why?
|
| Nervous System Malformations | 1 | 2005 | 12 | 0.250 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 1 | 2023 | 4 | 0.230 |
Why?
|
| Treatment Outcome | 3 | 2023 | 5142 | 0.220 |
Why?
|
| Delphi Technique | 1 | 2024 | 83 | 0.220 |
Why?
|
| Oxadiazoles | 1 | 2023 | 7 | 0.220 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2023 | 8 | 0.220 |
Why?
|
| Phototherapy | 1 | 2023 | 36 | 0.210 |
Why?
|
| Castleman Disease | 1 | 2022 | 5 | 0.210 |
Why?
|
| Mucositis | 1 | 2022 | 7 | 0.210 |
Why?
|
| Collagen Type VII | 1 | 2022 | 3 | 0.210 |
Why?
|
| Erythema | 1 | 2022 | 11 | 0.210 |
Why?
|
| Pemphigus | 1 | 2022 | 14 | 0.210 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2022 | 17 | 0.210 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2022 | 12 | 0.210 |
Why?
|
| Blister | 1 | 2022 | 17 | 0.210 |
Why?
|
| Nevus | 1 | 2022 | 18 | 0.200 |
Why?
|
| Wound Healing | 1 | 2023 | 177 | 0.200 |
Why?
|
| Antifungal Agents | 2 | 2017 | 117 | 0.200 |
Why?
|
| Funnel Chest | 1 | 2021 | 7 | 0.190 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 2323 | 0.190 |
Why?
|
| Cafe-au-Lait Spots | 2 | 2023 | 6 | 0.190 |
Why?
|
| Waxes | 1 | 2020 | 3 | 0.180 |
Why?
|
| Tongue | 1 | 2020 | 17 | 0.180 |
Why?
|
| Risk Assessment | 3 | 2019 | 1907 | 0.180 |
Why?
|
| Autoimmune Diseases | 1 | 2022 | 222 | 0.180 |
Why?
|
| Penis | 1 | 2020 | 23 | 0.180 |
Why?
|
| Emollients | 1 | 2020 | 5 | 0.180 |
Why?
|
| Baths | 1 | 2020 | 7 | 0.180 |
Why?
|
| Eczema | 1 | 2020 | 9 | 0.180 |
Why?
|
| Dermatitis, Atopic | 1 | 2020 | 21 | 0.180 |
Why?
|
| Anti-Bacterial Agents | 3 | 2020 | 721 | 0.180 |
Why?
|
| Chronic Pain | 1 | 2022 | 142 | 0.180 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2020 | 11 | 0.170 |
Why?
|
| Corneal Injuries | 1 | 2020 | 1 | 0.170 |
Why?
|
| Methadone | 1 | 2021 | 126 | 0.170 |
Why?
|
| Skin Care | 1 | 2020 | 7 | 0.170 |
Why?
|
| Keratitis | 1 | 2019 | 9 | 0.170 |
Why?
|
| Warts | 1 | 2019 | 6 | 0.170 |
Why?
|
| Melanoma | 1 | 2023 | 334 | 0.170 |
Why?
|
| Detergents | 1 | 2020 | 35 | 0.170 |
Why?
|
| Volunteers | 1 | 2019 | 17 | 0.170 |
Why?
|
| Psoriasis | 1 | 2020 | 51 | 0.170 |
Why?
|
| Dermatologists | 1 | 2019 | 11 | 0.170 |
Why?
|
| Blindness | 1 | 2020 | 37 | 0.170 |
Why?
|
| Child Care | 1 | 2019 | 20 | 0.170 |
Why?
|
| Staphylococcal Infections | 1 | 2020 | 114 | 0.170 |
Why?
|
| Cicatrix | 1 | 2020 | 58 | 0.170 |
Why?
|
| Down Syndrome | 1 | 2020 | 50 | 0.160 |
Why?
|
| Empathy | 1 | 2019 | 65 | 0.160 |
Why?
|
| Betacoronavirus | 1 | 2020 | 159 | 0.150 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 42 | 0.150 |
Why?
|
| Ketoconazole | 1 | 2017 | 8 | 0.150 |
Why?
|
| Fluconazole | 1 | 2017 | 14 | 0.150 |
Why?
|
| Torso | 1 | 2017 | 16 | 0.150 |
Why?
|
| Forehead | 1 | 2017 | 19 | 0.150 |
Why?
|
| Pruritus | 1 | 2017 | 29 | 0.150 |
Why?
|
| Patient Care Team | 1 | 2020 | 324 | 0.150 |
Why?
|
| Patch Tests | 3 | 2021 | 11 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 233 | 0.140 |
Why?
|
| Burnout, Professional | 1 | 2019 | 122 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 186 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 198 | 0.140 |
Why?
|
| Young Adult | 4 | 2022 | 4320 | 0.140 |
Why?
|
| Skin Pigmentation | 1 | 2016 | 32 | 0.130 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 1448 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 810 | 0.130 |
Why?
|
| Propylene Glycol | 1 | 2015 | 3 | 0.130 |
Why?
|
| Histamine Antagonists | 1 | 2015 | 5 | 0.130 |
Why?
|
| Pandemics | 1 | 2020 | 606 | 0.120 |
Why?
|
| Radiography | 1 | 2017 | 505 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 677 | 0.120 |
Why?
|
| Excipients | 1 | 2015 | 49 | 0.120 |
Why?
|
| Neoplasms | 1 | 2005 | 1234 | 0.120 |
Why?
|
| Inpatients | 1 | 2017 | 296 | 0.120 |
Why?
|
| Candidiasis, Cutaneous | 1 | 2014 | 2 | 0.120 |
Why?
|
| Adult | 7 | 2022 | 15735 | 0.120 |
Why?
|
| Dermatitis, Seborrheic | 1 | 2014 | 6 | 0.120 |
Why?
|
| Infant Welfare | 1 | 2014 | 7 | 0.110 |
Why?
|
| Hydroxides | 2 | 2005 | 7 | 0.110 |
Why?
|
| Potassium Compounds | 2 | 2005 | 9 | 0.110 |
Why?
|
| Pregnancy | 1 | 2021 | 2352 | 0.110 |
Why?
|
| Cheilitis | 1 | 2012 | 5 | 0.100 |
Why?
|
| Clobetasol | 1 | 2012 | 5 | 0.100 |
Why?
|
| Lip | 1 | 2012 | 13 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 157 | 0.090 |
Why?
|
| North America | 2 | 2021 | 114 | 0.090 |
Why?
|
| Canada | 2 | 2020 | 145 | 0.080 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 1020 | 0.080 |
Why?
|
| Comorbidity | 1 | 2012 | 1086 | 0.080 |
Why?
|
| Darier Disease | 1 | 2008 | 2 | 0.080 |
Why?
|
| Cephalexin | 1 | 2008 | 4 | 0.080 |
Why?
|
| Family Health | 1 | 2008 | 68 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 704 | 0.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2008 | 48 | 0.070 |
Why?
|
| Neutropenia | 1 | 2008 | 66 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2008 | 94 | 0.070 |
Why?
|
| Incidence | 2 | 2020 | 1232 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2020 | 837 | 0.060 |
Why?
|
| Mutation | 1 | 2012 | 2427 | 0.060 |
Why?
|
| Mosaicism | 1 | 2023 | 25 | 0.050 |
Why?
|
| Catastrophization | 1 | 2022 | 6 | 0.050 |
Why?
|
| Tinea | 1 | 2002 | 2 | 0.050 |
Why?
|
| Impetigo | 1 | 2002 | 3 | 0.050 |
Why?
|
| Hand Dermatoses | 1 | 2002 | 4 | 0.050 |
Why?
|
| Tinea Pedis | 1 | 2002 | 3 | 0.050 |
Why?
|
| Mycology | 1 | 2002 | 7 | 0.050 |
Why?
|
| Cellulitis | 1 | 2002 | 22 | 0.050 |
Why?
|
| Melanins | 1 | 2022 | 19 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2021 | 219 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 102 | 0.050 |
Why?
|
| Mupirocin | 1 | 2020 | 2 | 0.050 |
Why?
|
| Administration, Ophthalmic | 1 | 2020 | 1 | 0.040 |
Why?
|
| Ophthalmic Solutions | 1 | 2020 | 12 | 0.040 |
Why?
|
| Cosmetics | 1 | 2020 | 17 | 0.040 |
Why?
|
| Cornea | 1 | 2020 | 19 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 106 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2020 | 158 | 0.040 |
Why?
|
| Parents | 1 | 2022 | 379 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 126 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 254 | 0.040 |
Why?
|
| Age Distribution | 1 | 2019 | 261 | 0.040 |
Why?
|
| Self Care | 1 | 2020 | 211 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2019 | 553 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 366 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 846 | 0.030 |
Why?
|
| Hospitalization | 1 | 2024 | 1278 | 0.030 |
Why?
|
| Dermoscopy | 1 | 2016 | 11 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2016 | 66 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 732 | 0.030 |
Why?
|
| Ophthalmology | 1 | 2016 | 23 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 102 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 2588 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 1040 | 0.030 |
Why?
|
| Brain | 1 | 2022 | 1488 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 2463 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 2437 | 0.030 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2008 | 13 | 0.020 |
Why?
|
| Candidiasis, Vulvovaginal | 1 | 2008 | 8 | 0.020 |
Why?
|
| Pedigree | 1 | 2008 | 190 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2008 | 345 | 0.020 |
Why?
|
| Middle Aged | 1 | 2020 | 16238 | 0.010 |
Why?
|